Nurix Therapeutics (NRIX) vs Recursion Pharmaceuticals (RXRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Nurix Therapeutics (NRIX) has outperformed Recursion Pharmaceuticals (RXRX) over the past year, gaining 131.2% versus a loss of 18.4%. Over five years, NRIX leads with a -21.2% price change compared with -77.6% for RXRX. Nurix Therapeutics is the larger company by market cap ($2.36 billion vs $2.29 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NRIX | RXRX |
|---|---|---|
| Share price | $22.73 | $4.27 |
| Market cap | $2.36B | $2.29B |
| 1-day change | +0.58% | -7.78% |
| YTD return | +19.82% | +4.40% |
| 1-year return | +131.23% | -18.36% |
| 5-year return | -21.16% | -77.57% |
| EPS (TTM) | $-3.46 | $-1.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $28.23 | $7.18 |
| 52-week low | $9.00 | $2.77 |
| Distance from 52-week high | -19.48% | -40.53% |
| Analyst consensus | none | none |
| Avg. price target upside | +49.27% | +69.09% |
| Average volume | 1.27M | 20.28M |
| Shares outstanding | 103.78M | 535.34M |
| Employees | 317 | 600 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NRIX has outperformed RXRX by 149.6 percentage points over the past year.
About Nurix Therapeutics
NRIX stock →Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 317 employees
About Recursion Pharmaceuticals
RXRX stock →Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 600 employees
NRIX vs RXRX FAQ
Which is bigger, Nurix Therapeutics or Recursion Pharmaceuticals?
Nurix Therapeutics (NRIX) is larger, with a market capitalization of $2.36B compared with $2.29B for Recursion Pharmaceuticals (RXRX).
Which stock has performed better over the past year, NRIX or RXRX?
NRIX returned +131.23% over the past 12 months, compared with -18.36% for RXRX (price return, excluding dividends). Past performance does not predict future results.
Are Nurix Therapeutics and Recursion Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Nurix Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Recursion Pharmaceuticals.